ERBB2 and neoplasm: Using Oncotype DX®, three clinical trials showed that postmenopausal patients with an intermediate recurrence score (RS 11–25) and sHR-positive/HER2 negative tumours achieved excellent outcomes with endocrine therapy alone, even in those with one to three involved lymph nodes, classifying a large proportion of patients as low risk [20, 35, 36].